Prosena gets nonprofit boost

Share this article:

Nonprofit CureDuchenne is giving biotech Prosena $7 million to help its Duchenne Muscular Dystrophy treatment move along. CureDuchenne said in a statement Tuesday that the goal is to restart patients who had participated in other trials of exon-skipping drugs to begin receiving doses of Prosena's experimental drug drisapersen. The organization said the money is also going towards development of experimental drugs PRO045 or PRO053. CureDuchenne estimates drisapersen could help 13% of Duchenne patients, and that the latter drugs could help up to 8%.

Boys make up the majority of Duchenne patients and are typically diagnosed by the time they turn five.

The National Genome Institute says few patients live into their 30s.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.